Horm Metab Res 2017; 49(10): 778-785
DOI: 10.1055/s-0043-116944
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Height Increment and Laboratory Profile of Boys Treated With Aromatase Inhibitors With or Without Growth Hormone

Ludmila Fernandes Pedrosa
1   Pediatric Endocrinology Unit, Pediatrics Department, Irmandade da Santa Casa de Misericórdia de São Paulo, Santa Casa de Sao Paulo School of Medical Sciences, São Paulo, Brazil
,
Joice Marquez de Oliveira
2   Pediatric Endocrinology Unit, Pediatrics Department, Instituto da Criança do Hospital das Clínicas, Faculdade de Medicina da USP, São Paulo, Brazil
,
Paula Roberta Vieira Thomé
2   Pediatric Endocrinology Unit, Pediatrics Department, Instituto da Criança do Hospital das Clínicas, Faculdade de Medicina da USP, São Paulo, Brazil
,
Cristiane Kochi
1   Pediatric Endocrinology Unit, Pediatrics Department, Irmandade da Santa Casa de Misericórdia de São Paulo, Santa Casa de Sao Paulo School of Medical Sciences, São Paulo, Brazil
,
Durval Damiani
2   Pediatric Endocrinology Unit, Pediatrics Department, Instituto da Criança do Hospital das Clínicas, Faculdade de Medicina da USP, São Paulo, Brazil
,
Carlos Alberto Longui
1   Pediatric Endocrinology Unit, Pediatrics Department, Irmandade da Santa Casa de Misericórdia de São Paulo, Santa Casa de Sao Paulo School of Medical Sciences, São Paulo, Brazil
› Author Affiliations
Further Information

Publication History

received 07 February 2017

accepted 12 July 2017

Publication Date:
31 August 2017 (online)

Abstract

Aromatase inhibitors (AIs) have been used to recover height loss due to their capacity to delay growth plate closure. Long-term studies describing final heights are needed to determine the efficacy and safety profiles of these drugs for the treatment of impaired growth. This study aims to identify the therapeutic efficiency of AIs in improve growth and to describe potential adverse effects during treatment. Retrospective data analysis of 96 adolescents, among which 22 patients already attained near-final height, were followed at outpatient clinics of two referral centers. Patients were all in puberty and present idiopathic decrease in predicted adult height. Patients were treated with Anastrozole (ANZ: 1 mg/day) or Letrozole (LTZ: 2.5 mg/day) with/without recombinant human growth hormone (0.05 mg/kg/day) for 1.0 to 3.5 years (2.1±1.2 years). Height gain, body mass index, lipid, liver enzyme, gonadotropins and testosterone levels were described before and at the end of treatment. Predicted adult height (PAH) and NF height were compared with the TH. The height SDS (adjusted to bone age) significantly increased (p<0.05) in all groups [0.8±0.7 (ANZ), 0.7±0.7 (ANZ+GH), 0.3±0.5 (LTZ), and 1.2±0.8 (LTZ+GH)]; the latter group exhibited the highest increment of PAH and growth recovery to the TH (p<0.004). No significant side effects were observed. AI treatment, especially when used in association with GH was able to improve growth and the attainment of familial target height.

 
  • References

  • 1 Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80: 3689-3698
  • 2 Grumbach MM. Mutations in the synthesis and action of estrogen: the critical role in the male of estrogen on pubertal growth, skeletal maturation, and bone mass. Ann N Y Acad Sci 2004; 1038: 7-13
  • 3 Hero M, Norjavaara E, Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab 2005; 90: 6396-6402
  • 4 Hero M, Wickman S, Dunkel L. Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin Endocrinol (Oxford) 2006; 64: 510-513
  • 5 Mauras N, Gonzalez de Pijem L, Hsiang HY, Desrosiers P, Rapaport R, Schwartz ID, Klein KO, Singh RJ, Miyamoto A, Bishop K. Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years. J Clin Endocrinol Metab 2008; 93: 823-831
  • 6 Shams K, Cameo T, Fennoy I, Hassoun AA, Lerner SE, Aranoff GS, Sopher AB, Yang C, McMahon DJ, Oberfield SE. Outcome analysis of aromatase inhibitor therapy to increase adult height in males with predicted short adult stature and/or rapid pubertal progress: a retrospective chart review. J Pediatr Endocrinol Metab 2014; 27: 725-730
  • 7 Santen RJ, Brodie H, Simpson ER, Siiteri PK, Brodie A. History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev 2009; 30: 343-375
  • 8 Shim KS. Pubertal growth and epiphyseal fusion. Ann Pediatr Endocrinol Metab 2015; 20: 8-12
  • 9 Hero M. Aromatase inhibitors in the treatment of short stature. Endocr Develop 2016; 30: 130-140
  • 10 Salehpour S, Alipour P, Razzaghy-Azar M, Ardeshirpour L, Shamshiri A, Monfared MF, Gharib A. A double-blind, placebo-controlled comparison of letrozole to oxandrolone effects upon growth and puberty of children with constitutional delay of puberty and idiopathic short stature. Horm Res Paediatr 2010; 74: 428-435
  • 11 Nilsson O, Weise M, Landman EB, Meyers JL, Barnes KM, Baron J. Evidence that estrogen hastens epiphyseal fusion and cessation of longitudinal bone growth by irreversibly depleting the number of resting zone progenitor cells in female rabbits. Endocrinology 2014; 155: 2892-2899
  • 12 Lui JC, Nilsson O, Baron J. Recent research on the growth plate: recent insights into the regulation of the growth plate. J Mol Endocrinol 2014; 53: T1-T9
  • 13 Hero M, Toiviainen-Salo S, Wickman S, Mäkitie O, Dunkel L. Vertebral morphology in aromatase inhibitor-treated males with idiopathic short stature or constitutional delay of puberty. J Bone Mineral Res 2010; 25: 1536-1543
  • 14 Rothenbuhler A, Linglart A, Bougnères P. A randomized pilot trial of growth hormone with anastrozole versus growth hormone alone, starting at the very end of puberty in adolescents with idiopathic short stature. Int J Pediatr Endocrinol 2015; 2015 (1): 4
  • 15 Mauras N, Ross JL, Gagliardi P, Yu YM, Hossain J, Permuy J, Damaso L, Merinbaum D, Singh RJ, Gaete X, Mericq V. Randomized trial of aromatase inhibitors, growth hormone, or combination in pubertal boys with idiopathic short stature. J Clin Endocrinol Metab 2016; 101: 4984-4993
  • 16 Wickman S, Dunkel L. Inhibition of P450 aromatase enhances gonadotropin secretion in early and midpubertal boys: evidence for a pituitary site of action of endogenous E. J Clin Endocr Metab 2001; 86: 4887-4894
  • 17 Damiani D. Pharmacological management of children with short stature: the role of aromatase inhibitors. J Pediatria 2007; 83: S172-S177
  • 18 Wickman S, Saukkonen T, Dunkel L. The role of sex steroids in the regulation of insulin sensitivity and serum lipid concentrations during male puberty: a prospective study with a P450-aromatase inhibitor. Eur J Endocrinol 2002; 146: 339-346
  • 19 Hero M, Ankarberg-Lindgren C, Taskinen MR, Dunkel L. Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition. Eur J Endocrinol 2006; 155: 453-460